Short Interest in Caring Brands, Inc. (NASDAQ:CABR) Grows By 1,337.5%

Caring Brands, Inc. (NASDAQ:CABR) was the recipient of a large increase in short interest during the month of August. As of August 14th, there was short interest totaling 6,138 shares, an increase of 1,337.5% from the July 30th total of 427 shares. Based on an average daily trading volume, of 137,498 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.1% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Caring Brands from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 11th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Caring Brands Trading Up 3.5%

NASDAQ:CABR opened at $1.33 on Thursday. The company has a market capitalization of $13.79 million and a P/E ratio of -1.80. The company has a current ratio of 4.96, a quick ratio of 4.93 and a debt-to-equity ratio of 0.03. Caring Brands has a 12 month low of $0.71 and a 12 month high of $5.35. The firm has a fifty day simple moving average of $1.37 and a 200-day simple moving average of $1.15.

Caring Brands (NASDAQ:CABR) last issued its earnings results on Thursday, August 13th. The company reported ($0.10) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Caring Brands

An institutional investor recently bought a new stake in Caring Brands stock. Susquehanna International Group LLP purchased a new position in Caring Brands, Inc. (NASDAQ:CABR) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 20,771 shares of the company’s stock, valued at approximately $26,000. Susquehanna International Group LLP owned 0.20% of Caring Brands at the end of the most recent quarter.

About Caring Brands

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.